P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management

Yuyang ZhangHaiming KouZhipeng ChengXuan LuYU HULiang Tang^*

• Huazhong University of Science and Technology Tongji Medical College Union Hospital, Wuhan, China

Given the rarity of natural killer/T-cell lymphoma (NKTL), this study represents a relatively large-scale clinical investigation into this disease, which exhibits suboptimal responses to existing therapeutic protocols. In this study, we report the efficacy of the P3-GemOx regimen (mitoxantrone hydrochloride liposome [Plm60] combined with the PP-GemOx [anti-Programmed death-1 antibody, Pegaspargase, GEMcitabine, and OXaliplatin] regimen) compared to the traditional PP-GemOx regimen in advanced NKTL. Eleven patients received a median of 3 cycles (range, 1-4) of the P3-GemOx regimen every 3-4 weeks, while another eleven patients received a median of 4 cycles (range, 2-6) of the PP-GemOx regimen, also every 3-4 weeks. Treatment responses were primarily assessed using 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) and computed tomography or magnetic resonance imaging. All patients treated with the P3-GemOx regimen exhibited significant responses, with nine complete remissions (CR) and two partial remissions (PR), resulting in an overall response rate (ORR) of 100%. Moreover, seven of these patients successfully underwent hematopoietic stem cell transplantation (HSCT). In contrast, the ORR for patients receiving the PP-GemOx regimen was 63.6%, with none undergoing HSCT. All adverse events were manageable and resolved. In conclusion, the P3-GemOx regimen demonstrates superior efficacy in advanced NKTL.